Mad Money w/ Jim Cramer Mad Money w/ Jim Cramer 1/12/26
5 snips
Jan 13, 2026 Mike Deustar, President and CEO of Novo Nordisk, dives into the groundbreaking launch of their oral GLP-1 pill, addressing its cardiovascular benefits and pricing strategies. Jeff Marthin, CEO of Medtronic, shares insights on innovative FDA-approved devices like the smart glucose pen and the company's ambitious diabetes spin-off plans. Albert Borla, Chairman of Pfizer, explores their weight-loss initiatives and acquisition strategies amid looming loss of exclusivity. Finally, Brent Saunders, CEO of Bausch & Lomb, reveals exciting advancements in eye care and a robust growth plan.
AI Snips
Chapters
Transcript
Episode notes
Markets Ignore Political Theater
- The market often dismisses extreme political moves as unlikely to be carried out and prices accordingly.
- Jim Cramer argues investors should watch whether actions actually affect Fed independence or lending behavior.
Consider Buying Shopify On Dip
- Cramer recommends buying Shopify on recent weakness and riding the rally.
- He says Shopify is a buy and expects it to go higher after the day's rally.
Oral GLP-1 Matches Injectable Efficacy
- Novo Nordisk launched an oral semaglutide that matches injectable weight-loss efficacy at ~16.6% in trials.
- Mike Deustar says the pill expands access by avoiding injections and refrigeration challenges in many markets.